-transparent.png){kind=logo}
Sixteen patients with metastatic melanoma entered this phase II study of the efficacy of monthly cycles of Bisantrene. Toxicity was characterized by leukopenia, resulting in the hospitalization of one patient for a febrile incident, and superficial phlebitis. The results were similar to those of previous studies, in that among the 13 patients evaluable for response (six previously untreated with chemotherapy) there were no responses.
Related Publications
P J Stiff, and
D Sweet, and
L J Kilton, and
C M Johnson, and
B Muntean, and
R R Blough
September 1983,
Cancer treatment reports,
P J Stiff, and
D Sweet, and
L J Kilton, and
C M Johnson, and
B Muntean, and
R R Blough
August 1990,
Investigational new drugs,
P J Stiff, and
D Sweet, and
L J Kilton, and
C M Johnson, and
B Muntean, and
R R Blough
August 1986,
Cancer treatment reports,
P J Stiff, and
D Sweet, and
L J Kilton, and
C M Johnson, and
B Muntean, and
R R Blough
January 1994,
Investigational new drugs,
P J Stiff, and
D Sweet, and
L J Kilton, and
C M Johnson, and
B Muntean, and
R R Blough
July 1989,
Investigational new drugs,
P J Stiff, and
D Sweet, and
L J Kilton, and
C M Johnson, and
B Muntean, and
R R Blough
July 1989,
Investigational new drugs,
P J Stiff, and
D Sweet, and
L J Kilton, and
C M Johnson, and
B Muntean, and
R R Blough
September 1987,
Cancer treatment reports,
P J Stiff, and
D Sweet, and
L J Kilton, and
C M Johnson, and
B Muntean, and
R R Blough
March 1985,
Cancer treatment reports,
P J Stiff, and
D Sweet, and
L J Kilton, and
C M Johnson, and
B Muntean, and
R R Blough
February 1990,
Investigational new drugs,
P J Stiff, and
D Sweet, and
L J Kilton, and
C M Johnson, and
B Muntean, and
R R Blough
January 1986,
European journal of cancer & clinical oncology,
